A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group
Article in Annals of Hematology (September 2023)
The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.
Immunotherapeutic Development of a Tri-Specific NK Cell Engager Recognizing BCMA
Article in Immuno (June 2023)
Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma
Article in Chinese Journal of Hematology (June 2023)